NCT05792540CompletedPhase 2
Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
Major depressive disorder (MDD) is a significant cause of disability that affects approximately 16% of the world's population and is associated with chronic inflammation. Although the mechanisms of MDD have not yet been clearly elucidated, NLRP3 inflammasomes have been implicated in the pathogenesis of depression.NLRP3 inflammasome is an intracellular multiprotein complex that consists of nod-like receptor protein 3, an adaptor protein, and a procaspase-1 precursor. It is well known that a variety of danger signals, such as pathogen-associated molecular patterns and danger-associated molecular patterns can activate NLRP3 inflammasome
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- First submitted
- 19 Mar 2023
- Start date
- 6 Jun 2023
- Primary completion date
- 20 Dec 2023
- Lead sponsor
- Tanta University
- Diseases
- Depression
- NCT number
- NCT05792540
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 75
- From 6 Jun 2023 to the primary completion date, 20 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with concurrent active medical conditions
- Patients with a history of receiving Electroconvulsive therapy (ECT)
Other illness
- Patients with bipolar I or bipolar II disorder
- Patients with personality disorders
- Patients with eating disorders
- Patients with a history of seizures
- Patients with inflammatory disorders
- Patients with allergies or contraindications to the used medications
Other
- Patients with substance dependence or abuse
- Patients with finally pregnant or lactating females
- Diabetic or hyperlipidaemic patients
Who the study is looking for
- \- Age ≥ 18 years Both males and females will be included Negative pregnancy test and effective contraception. Depressed patients for at least 2 months with a Hamilton rating score of more than 18.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Medicine, Menoufia University Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.